Cargando…
A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288729/ http://dx.doi.org/10.1186/2051-1426-2-S3-P71 |
| _version_ | 1782352015125381120 |
|---|---|
| author | Meyerhardt, Jeffrey A Grady, Michele M Lowe, Jamie N Gargano, Michele A Huhn, Richard D Braun, Ada H |
| author_facet | Meyerhardt, Jeffrey A Grady, Michele M Lowe, Jamie N Gargano, Michele A Huhn, Richard D Braun, Ada H |
| author_sort | Meyerhardt, Jeffrey A |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288729 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42887292015-01-15 A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer Meyerhardt, Jeffrey A Grady, Michele M Lowe, Jamie N Gargano, Michele A Huhn, Richard D Braun, Ada H J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288729/ http://dx.doi.org/10.1186/2051-1426-2-S3-P71 Text en Copyright © 2014 Meyerhardt et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Meyerhardt, Jeffrey A Grady, Michele M Lowe, Jamie N Gargano, Michele A Huhn, Richard D Braun, Ada H A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title | A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title_full | A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title_fullStr | A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title_full_unstemmed | A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title_short | A Phase III open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| title_sort | phase iii open-label, randomized, multicenter study of imprime pgg in combination with cetuximab in patients with kras wild type metastatic colorectal cancer |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288729/ http://dx.doi.org/10.1186/2051-1426-2-S3-P71 |
| work_keys_str_mv | AT meyerhardtjeffreya aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT gradymichelem aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT lowejamien aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT garganomichelea aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT huhnrichardd aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT braunadah aphaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT meyerhardtjeffreya phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT gradymichelem phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT lowejamien phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT garganomichelea phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT huhnrichardd phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer AT braunadah phaseiiiopenlabelrandomizedmulticenterstudyofimprimepggincombinationwithcetuximabinpatientswithkraswildtypemetastaticcolorectalcancer |